International Stem Cell Corp. (ISCO) Proclaims Liver Disease Program’s Success
International Stem Cell Corporation, a company specializing in the therapeutic applications of human parthenogenetic stem cells (hpSCs), today reported positive top line efficacy results from its pre-clinical in vivo liver study. The main goal of this study was to demonstrate the therapeutic equivalence of human parthenogenetic stem cell (hpSC)-derived hepatocytes to adult liver cells as a prerequisite for using such cells in the treatment of metabolic liver diseases, including Crigler-Najjar Syndrome (CNS). CNS is a rare inherited disorder in which bilirubin cannot be broken down by the liver. The build-up of this toxic compound can result in damage to the…